BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol. 2008;13:498-503. [PMID: 19093176 DOI: 10.1007/s10147-008-0854-3] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 van Kuilenburg ABP, Etienne-grimaldi M, Mahamat A, Meijer J, Laurent-puig P, Olschwang S, Gaub M, Hennekam RCM, Benchimol D, Houry S, Letoublon C, Gilly F, Pezet D, Andre T, Faucheron J, Abderrahim-ferkoune A, Vijzelaar R, Pradere B, Milano G. Frequent intragenic rearrangements of DPYD in colorectal tumours. Pharmacogenomics J 2015;15:211-8. [DOI: 10.1038/tpj.2014.68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Pfütze K, Benner A, Hoffmeister M, Jansen L, Yang R, Bläker H, Herpel E, Ulrich A, Ulrich CM, Chang-Claude J, Brenner H, Burwinkel B. Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. Genomics 2015;106:348-54. [PMID: 26453961 DOI: 10.1016/j.ygeno.2015.10.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
3 Wang Y, Tian X, Liang L, Wang Y, Wang R, Cheng X, Yan Z, Chen Y, Qi P. Mechanistic Study on Triptorelin Action in Protecting From 5-FU-Induced Ovarian Damage in Rats. Oncol Res 2014;22:283-92. [PMID: 26629940 DOI: 10.3727/096504015X14410238486720] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Bahrami A, Hesari A, Khazaei M, Hassanian SM, Ferns GA, Avan A. The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. J Cell Physiol 2018;233:2162-9. [DOI: 10.1002/jcp.25952] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
5 Tänzer M, Liebl M, Quante M. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. Pharmacol Ther. 2013;140:133-147. [PMID: 23791941 DOI: 10.1016/j.pharmthera.2013.06.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
6 Loh M, Liem N, Vaithilingam A, Lim PL, Sapari NS, Elahi E, Mok ZY, Cheng CL, Yan B, Pang B, Salto-Tellez M, Yong WP, Iacopetta B, Soong R. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. BMC Gastroenterol. 2014;14:55. [PMID: 24674026 DOI: 10.1186/1471-230x-14-55] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
7 Yang Q, Dong Y, Wu W, Zhu C, Chong H, Lu J, Yu D, Liu L, Lv F, Wang S. Detection and differential diagnosis of colon cancer by a cumulative analysis of promoter methylation. Nat Commun 2012;3:1206. [PMID: 23149750 DOI: 10.1038/ncomms2209] [Cited by in F6Publishing: 52] [Reference Citation Analysis]
8 Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011;21:237-242. [PMID: 20601926 DOI: 10.1097/fpc.0b013e32833c6107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
9 Ng JM, Yu J. Promoter hypermethylation of tumour suppressor genes as potential biomarkers in colorectal cancer. Int J Mol Sci. 2015;16:2472-2496. [PMID: 25622259 DOI: 10.3390/ijms16022472] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 12.1] [Reference Citation Analysis]
10 Carethers JM, Jung BH. Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology 2015; 149: 1177-1190. e3. [PMID: 26216840 DOI: 10.1053/j.gastro.2015.06.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 195] [Article Influence: 28.3] [Reference Citation Analysis]
11 Sebio A, Lenz H. The Molecular Taxonomy of Colorectal Cancer: What’s New? Curr Colorectal Cancer Rep 2015;11:118-24. [DOI: 10.1007/s11888-015-0267-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Liu L, Lin J, He H. Identification of Potential Crucial Genes Associated With the Pathogenesis and Prognosis of Endometrial Cancer. Front Genet 2019;10:373. [PMID: 31105744 DOI: 10.3389/fgene.2019.00373] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
13 Miozzo M, Vaira V, Sirchia SM. Epigenetic alterations in cancer and personalized cancer treatment. Future Oncology 2015;11:333-48. [DOI: 10.2217/fon.14.237] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
14 Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol 2014; 20(14): 3858-3874 [PMID: 24744578 DOI: 10.3748/wjg.v20.i14.3858] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
15 Grady WM, Markowitz SD. The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci. 2015;60:762-772. [PMID: 25492499 DOI: 10.1007/s10620-014-3444-4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 9.6] [Reference Citation Analysis]
16 Kim SE. Enzymes involved in folate metabolism and its implication for cancer treatment. Nutr Res Pract 2020;14:95-101. [PMID: 32256983 DOI: 10.4162/nrp.2020.14.2.95] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hokazono K, Ueki T, Nagayoshi K, Nishioka Y, Hatae T, Koga Y, Hirahashi M, Oda Y, Tanaka M. A CpG island methylator phenotype of colorectal cancer that is contiguous with conventional adenomas, but not serrated polyps. Oncol Lett 2014;8:1937-44. [PMID: 25289081 DOI: 10.3892/ol.2014.2430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wigmore PM, Mustafa S, El-Beltagy M, Lyons L, Umka J, Bennett G. Effects of 5-FU. Adv Exp Med Biol 2010;678:157-64. [PMID: 20738018 DOI: 10.1007/978-1-4419-6306-2_20] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
19 Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer. 2011;11:344. [PMID: 21827707 DOI: 10.1186/1471-2407-11-344] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
20 Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruïne AP, Carvalho B, Meijer GA, Schouten LJ, van den Brandt PA, Weijenberg MP. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Ann Oncol. 2013;24:2048-2056. [PMID: 23532114 DOI: 10.1093/annonc/mdt076] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
21 Pardo OE, Seckl MJ. S6K2: The Neglected S6 Kinase Family Member. Front Oncol 2013;3:191. [PMID: 23898460 DOI: 10.3389/fonc.2013.00191] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
22 Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol. 2011;225:336-343. [PMID: 21660972 DOI: 10.1002/path.2879] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.9] [Reference Citation Analysis]
23 Abdelfatah E, Kerner Z, Nanda N, Ahuja N. Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol. 2016;9:560-579. [PMID: 27366224 DOI: 10.1177/1756283x16644247] [Cited by in Crossref: 62] [Cited by in F6Publishing: 24] [Article Influence: 10.3] [Reference Citation Analysis]
24 Molinari C, Casadio V, Foca F, Zingaretti C, Giannini M, Avanzolini A, Lucci E, Saragoni L, Passardi A, Amadori D. Gene methylation in rectal cancer: predictive marker of response to chemoradiotherapy? J Cell Physiol. 2013;228:2343-2349. [PMID: 23702823 DOI: 10.1002/jcp.24405] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
25 van der Sijp MP, Bastiaannet E, Mesker WE, van der Geest LG, Breugom AJ, Steup WH, Marinelli AW, Tseng LN, Tollenaar RA, van de Velde CJ, Dekker JW. Differences between colon and rectal cancer in complications, short-term survival and recurrences.Int J Colorectal Dis. 2016;31:1683-1691. [PMID: 27497831 DOI: 10.1007/s00384-016-2633-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
26 Droy-dupré L, Bossard C, Volteau C, Bezieau S, Laboisse CL, Mosnier J. Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis. Virchows Arch 2015;466:383-91. [DOI: 10.1007/s00428-015-1724-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Fouad MA, Salem SE, Hussein MM, Zekri ARN, Hafez HF, El Desouky ED, Shouman SA. Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients. Front Pharmacol 2018;9:1173. [PMID: 30405408 DOI: 10.3389/fphar.2018.01173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
28 Zhang X, Shimodaira H, Soeda H, Komine K, Takahashi H, Ouchi K, Inoue M, Takahashi M, Takahashi S, Ishioka C. CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. Int J Clin Oncol 2016;21:1091-101. [PMID: 27435270 DOI: 10.1007/s10147-016-1017-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
29 Dawson H, Galván JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A, Zlobec I. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer 2014;134:2342-51. [PMID: 24166180 DOI: 10.1002/ijc.28564] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
30 Schirripa M, Cohen SA, Battaglin F, Lenz HJ. Biomarker-driven and molecular targeted therapies for colorectal cancers. Semin Oncol 2018;45:124-32. [PMID: 30262397 DOI: 10.1053/j.seminoncol.2017.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
31 Stadler ZK. Diagnosis and management of DNA mismatch repair-deficient colorectal cancer. Hematol Oncol Clin North Am 2015;29:29-41. [PMID: 25475571 DOI: 10.1016/j.hoc.2014.09.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
32 Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data. Eur J Cancer. 2010;46:2788-2798. [PMID: 20627535 DOI: 10.1016/j.ejca.2010.05.009] [Cited by in Crossref: 250] [Cited by in F6Publishing: 237] [Article Influence: 20.8] [Reference Citation Analysis]
33 Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol 2014; 20(29): 9775-9827 [PMID: 25110414 DOI: 10.3748/wjg.v20.i29.9775] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 75] [Article Influence: 9.3] [Reference Citation Analysis]
34 Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. J Intern Med 2013;274:1-24. [PMID: 23527888 DOI: 10.1111/joim.12070] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
35 Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, Herman JG, Weijenberg MP, van Engeland M. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochim Biophys Acta. 2012;1825:77-85. [PMID: 22056543 DOI: 10.1016/j.bbcan.2011.10.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 67] [Article Influence: 1.5] [Reference Citation Analysis]
36 Murcia O, Juárez M, Hernández-Illán E, Egoavil C, Giner-Calabuig M, Rodríguez-Soler M, Jover R. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy. World J Gastroenterol 2016; 22(13): 3516-3530 [PMID: 27053844 DOI: 10.3748/wjg.v22.i13.3516] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
37 Samadder NJ, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology. 2013;145:348-356.e1-2. [PMID: 23665275 DOI: 10.1053/j.gastro.2013.05.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
38 Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, Kim YS. Promoter Methylation of Specific Genes is Associated with the Phenotype and Progression of Colorectal Adenocarcinomas. Ann Surg Oncol 2010;17:1767-76. [DOI: 10.1245/s10434-009-0901-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
39 Sarabi MM, Naghibalhossaini F. Association of DNA methyltransferases expression with global and gene-specific DNA methylation in colorectal cancer cells. Cell Biochem Funct. 2015;33:427-433. [PMID: 26416384 DOI: 10.1002/cbf.3126] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
40 Grady WM, Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol 2014;42:124-39. [PMID: 24178577 DOI: 10.1177/0192623313505155] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
41 Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011;8:686-700. [PMID: 22009203 DOI: 10.1038/nrgastro.2011.173] [Cited by in Crossref: 381] [Cited by in F6Publishing: 360] [Article Influence: 34.6] [Reference Citation Analysis]
42 Kim SE, Hinoue T, Kim MS, Sohn KJ, Cho RC, Cole PD, Weisenberger DJ, Laird PW, Kim YI. γ-Glutamyl hydrolase modulation significantly influences global and gene-specific DNA methylation and gene expression in human colon and breast cancer cells. Genes Nutr 2015;10:444. [PMID: 25502219 DOI: 10.1007/s12263-014-0444-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
43 Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G. Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol 2013;13:36. [PMID: 23446022 DOI: 10.1186/1471-230X-13-36] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
44 Moradi Sarabi M, Mohammadrezaei Khorramabadi R, Zare Z, Eftekhar E. Polyunsaturated fatty acids and DNA methylation in colorectal cancer. World J Clin Cases 2019; 7(24): 4172-4185 [PMID: 31911898 DOI: 10.12998/wjcc.v7.i24.4172] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
45 Kim CJ, Jung YS, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Lee SY, Kim HM, Bang KB, Lee DS, Park DI. Prevalence, Clinicopathologic Characteristics, and Predictors of Interval Colorectal Cancers in Korean Population. Intest Res 2013;11:178. [DOI: 10.5217/ir.2013.11.3.178] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
46 Cha Y, Kim KJ, Han SW, Rhee YY, Bae JM, Wen X, Cho NY, Lee DW, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Kang GH, Kim TY. Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer. Br J Cancer 2016;115:164-71. [PMID: 27310704 DOI: 10.1038/bjc.2016.176] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
47 Messick CA, Sanchez J, Dejulius KL, Church JM, Kalady MF. Genetic and molecular diversity of colon cancer hepatic metastases. Surgery 2009;146:227-31. [PMID: 19628078 DOI: 10.1016/j.surg.2009.06.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
48 Ham MS, Lee JK, Kim KC. S-adenosyl methionine specifically protects the anticancer effect of 5-FU via DNMTs expression in human A549 lung cancer cells. Mol Clin Oncol 2013;1:373-8. [PMID: 24649178 DOI: 10.3892/mco.2012.53] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
49 Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-29. [PMID: 20921207 DOI: 10.1136/gut.2009.206250] [Cited by in Crossref: 210] [Cited by in F6Publishing: 200] [Article Influence: 17.5] [Reference Citation Analysis]
50 Yi JH, Liu J, Wang KH. CpG island methylator phenotype in colorectal cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(4): 558-565 [DOI: 10.11569/wcjd.v24.i4.558] [Reference Citation Analysis]
51 Fang M, Ou J, Hutchinson L, Green MR. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Mol Cell. 2014;55:904-915. [PMID: 25219500 DOI: 10.1016/j.molcel.2014.08.010] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 15.3] [Reference Citation Analysis]
52 Bae JM, Kim MJ, Kim JH, Koh JM, Cho N, Kim T, Kang GH. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Arch 2011;459:55-63. [DOI: 10.1007/s00428-011-1080-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]
53 Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM; Alliance for Clinical Trials in Oncology. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 2014;147:637-45. [PMID: 24859205 DOI: 10.1053/j.gastro.2014.05.009] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 11.5] [Reference Citation Analysis]
54 Weisenberger DJ, Liang G, Lenz HJ. DNA methylation aberrancies delineate clinically distinct subsets of colorectal cancer and provide novel targets for epigenetic therapies. Oncogene. 2018;37:566-577. [PMID: 28991233 DOI: 10.1038/onc.2017.374] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]